Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control. The Quality-Adjusted Time without Symptoms or ...
Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) methodology was used to compare treatments where survival was partitioned into three health states ...
Welireg significantly improved quality-adjusted survival time over Afinitor in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. The relative gain in Q-TWiST with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback